Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 18, 2008. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding an increase in their personal holdings of Ordinary shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details. The transaction prices noted were GBP10.73 per Ordinary share and $43.32 per ADR.
Material Changes
There are no material changes to financial performance or operations reported in this document. The only reported activity is the re-investment of dividends paid to shareholders on April 10, 2008, by specific company officers.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- The filing details share purchases by six individuals: Dr M M Slaoui, Mrs C E Bruck Slaoui, Mr EJ Gray, Mr D Learmouth, Mr W C Louv, and Mr S M Werner.
- The transactions resulted from the re-investment of dividends paid on April 10, 2008.
- The specific number of shares or ADRs acquired by each individual is not listed in the provided text, only the transaction prices.
- This report does not contain financial results or operational updates for the company.